U.S. markets closed
  • S&P Futures

    3,739.50
    -26.00 (-0.69%)
     
  • Dow Futures

    30,705.00
    -173.00 (-0.56%)
     
  • Nasdaq Futures

    12,333.75
    -121.25 (-0.97%)
     
  • Russell 2000 Futures

    2,118.00
    -26.50 (-1.24%)
     
  • Crude Oil

    64.07
    +0.24 (+0.38%)
     
  • Gold

    1,687.30
    -13.40 (-0.79%)
     
  • Silver

    25.18
    -0.28 (-1.10%)
     
  • EUR/USD

    1.1959
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • Vix

    28.57
    +1.90 (+7.12%)
     
  • GBP/USD

    1.3880
    -0.0014 (-0.10%)
     
  • USD/JPY

    107.9180
    -0.0580 (-0.05%)
     
  • BTC-USD

    46,931.11
    -4,461.77 (-8.68%)
     
  • CMC Crypto 200

    938.15
    -49.06 (-4.97%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,345.51
    -584.60 (-2.02%)
     

VivoPower Shares Rise More Than 100% After Update On Solar Portfolio Sale, New Contracts

  • Oops!
    Something went wrong.
    Please try again later.
Tanzeel Akhtar
  • Oops!
    Something went wrong.
    Please try again later.

VivoPower International PLC (NASDAQ: VVPR) shares traded sharply higher Monday after the company announced new parties have engaged in the company's U.S. solar portfolio sale.

VivoPower International also said that its Australian power services businesses, Kenshaw Electrical Pty Limited and J.A. Martin Electrical Pty Limited, have secured additional contracts relating to solar farms and data centers worth $22.6 million.

With these new contracts, VivoPower's forward order book for power services has now increased to $51.5 million on the back of this and the previous contract wins in the data center, solar, agriculture, transport, mining and utility sectors, according to the company.

This represents an increase of 53% in the last seven months and is another new all-time record high for the company's forward order book. VivoPower said it expects the contracts will be fulfilled within the next 12 months.

The stock was trading higher by 105.76% at $2.15 late in Monday's session.

Related Links:

Mid-Day Market Update: PCM Jumps Following Acquisition News; 360 Finance Shares Slide

Mesoblast Trades Higher After Heart Failure Cell Therapy Receives Orphan Drug Status

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.